US-based pharmaceutical firm dedicated to the commercialization of oncology treatment and oncology supportive care products DARA BioSciences has signed a pharmacy supply agreement with RainTree Oncology Services.
The agreement is for both Gelclair, an FDA-approved bioadherent oral rinse gel for treating the painful symptoms of oral mucositis (OM), and Soltamox (tamoxifen citrate) oral liquid solution, to be accessible to RainTree’s Nationwide Oncology Membership.
RainTree Oncology Services assists its member practices in providing effective treatments to oncology patients, while developing commercial relationships that speed up new oncology treatments and payer arrangements optimizing oncology patient care and advancing the practice of oncology.
The deal with RainTree Oncology Services gives RainTree member practices access to DARA’s products.
Both the firms will work to provide both products to the RainTree nationwide oncology membership, many of which have in-house pharmaceutical dispensing services.
DARA BioSciences CEO and chief medical officer David Drutz said the company believes that Gelclair and Soltamox address important therapeutic needs for thousands of patients treated by RainTree member practices and present a new opportunity to service the needs of patients suffering from cancer and cancer treatment side effects directly at the point of care.
“We are excited with the opportunity to offer product access to RainTree’s member practices for both Soltamox and Gelclair and the opportunity to collaborate with them on this front,” Drutz said.
DARA president and COO Christopher Clement said following the recent signing of the two-year exclusive agreement with Memorial Sloan Kettering for formulary access for Gelclair, the company continues to work closely with other oncology market leaders in pursuit of additional agreements to optimize the utilization of its product portfolio.
“These relationships, in concert with the launch of our newly instituted 20 person national sales force earlier this month, are important drivers for what we anticipate to be an exciting 2014 for DARA,” Clement said.
